Recent News

• 02.05.2026 - Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update
• 02.03.2026 - Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA)
• 01.30.2026 - Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA
• 01.23.2026 - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 01.12.2026 - Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference
• 01.07.2026 - Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference
• 12.30.2025 - Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
• 12.29.2025 - Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta

Recent Filings

• 02.05.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.03.2026 - 8-K Current report
• 02.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.02.2026 - 144 Report of proposed sale of securities
• 01.30.2026 - 8-K Current report
• 01.12.2026 - EX-99.1 EX-99.1
• 01.12.2026 - 8-K Current report
• 01.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.02.2026 - 144 Report of proposed sale of securities
• 12.30.2025 - 8-K Current report